The NGOs Delegation to UNITAID Board are pleased to announce that Dr. Tido von Schoen-Angerer, Executive Directorof the Campaign for Access to Essential Medicines of Médecins Sans Frontières, has been selected to the role of UNITAID Alternate Board member for NGOs.
The NGO Alternate Board member selection process took place in June 2011 and was convened by the Civil Society delegations’ Liaison Officer. A selection panel was utilised, consisting of existing delegation Board member and Alternate, two members of the delegation Advisory Group (NGOs), and one NGO representative external to the delegations. The position was advertised for 4 weeks, and the candidate chosen following a shortlisting process (scoring against the essential/desirable criteria for the post) and a subsequent interview.
The Civil Society delegations would like to take this opportunity to welcome Dr. von Schoen-Angerer to the delegations, and to thank Dr. Mohga Kamal Yanni, outgoing Board member (Oxfam GB), for her excellent contribution to the Civil Society Delegations to UNITAID. The delegations welcome Dr. Kamal-Yanni’s continued input as a key advisor to the delegation.
For more information on the selection of the new NGOs Alternate Board member, please contact the Civil Society delegations Liaison Officer, Jessica Hamer, [email protected]
Tido von Schoen-Angerer, M.D., M.Sc. has been the Executive Director of Médecins Sans Frontières/Doctors Without Borders (MSF)’s Campaign for Access to Essential Medicines based in Geneva,Switzerland since 2006. Tido studied medicine in Mainz, Germany and Uppsala, Sweden. He was a pediatric resident at the Albert Einstein College of Medicine, Bronx, New York and holds a Master in Public Health from the London School of Hygiene and Tropical Medicine. He joined MSF for the first time in 1995 and has since 1999 been with MSF in different field and headquarter positions. Tido worked in Armenia, Zimbabwe and Thailand and led projects in Nigeria, Chad, Bangladesh and Indonesia. His interest is in the problems of access to medicines and insufficient innovation for diseases that primarily affectpeople in poor countries.